Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Engage Grants Program

University of Waterloo

$25,000.00

Human Intestinal Glucosidases: Counter-screening of novel therapeutics

FY 2018-19

Summary
Alectos Therapeutics, a spin-off company from Simon Fraser University in Burnaby, BC, is dedicated to the*development of novel therapeutics for serious diseases. Most of these compounds are targeted to regulate*enzymes involved in the synthesis or breakdown of sugar complexes called glycans. These could potentially be*applied to growing health concerns, including Alzheimer's and Parkinson's Diseases and other neurological*conditions.*Glycans are present everywhere in our body, and the enzymes that make or degrade them are essential to*many aspects of health. Therefore, it is important that any new compounds do not have side-effects that could*affect normal activities. The goal of this project is to assist the company in screening their new therapeutic*compounds against important glycan processing enzymes, to make sure there are not unwanted affects.*The enzymes under study here are located in the human intestine and are the primary activities for breaking*down starch and sucrose, major components of our diet, into glucose for energy. Inhibition of these enzymes,*maltase-glucoamylase (MGAM) and sucrase-isomaltase (SI), would lead to serious consequences, such as*major food intolerances. The goal of the proposal is to provide Alectos with quantities of these enzymes for*cross-screening their promising compounds. As these enzymes are large, human proteins, they have to be*produced in eukaryotic cells, to ensure native activity.*The applicant's laboratory is preparing the enzymes in a yeast cell culture system. The funding would allow*production of sufficient quantities of both human intestinal enzymes for cross-screening by the company. If*unwanted activities are seen, the applicant will assist the company in investigating the causes of those activities*and improving the specificity of their compounds.
Program
Engage Grants Program
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data

As published

Application id
526375-2018
Name nom
Rose, David
Department département
Biology
Organization id
33
Institution établissement
University of Waterloo
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2018
Competition year année de concours
2018
Award amount
25000
Program id
EGP
Program name en
Engage Grants Program
Program name fr
Programme de subventions d'engagement partenariat
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
1553
Committee name en
Ontario Internal Decision Committee
Committee name fr
Comité de décision interne pour l'Ontario
Area of application code
1201
Area of application group en
Advancement of knowledge
Area of application group fr
Avancement des connaissances
Area of application en
Life sciences (including biotechnology)
Area of application fr
Sciences de la vie (y compris biotechnologie)
Research subject code
5404
Research subject group en
Biochemistry
Research subject group fr
Biochimie
Research subject en
Enzymes
Research subject fr
Enzymes
Partie
1
Nb partie
1
Application title
Human Intestinal Glucosidases: Counter-screening of novel therapeutics
Keyword
NSERC
Application summary
Alectos Therapeutics, a spin-off company from Simon Fraser University in Burnaby, BC, is dedicated to the*development of novel therapeutics for serious diseases. Most of these compounds are targeted to regulate*enzymes involved in the synthesis or breakdown of sugar complexes called glycans. These could potentially be*applied to growing health concerns, including Alzheimer's and Parkinson's Diseases and other neurological*conditions.*Glycans are present everywhere in our body, and the enzymes that make or degrade them are essential to*many aspects of health. Therefore, it is important that any new compounds do not have side-effects that could*affect normal activities. The goal of this project is to assist the company in screening their new therapeutic*compounds against important glycan processing enzymes, to make sure there are not unwanted affects.*The enzymes under study here are located in the human intestine and are the primary activities for breaking*down starch and sucrose, major components of our diet, into glucose for energy. Inhibition of these enzymes,*maltase-glucoamylase (MGAM) and sucrase-isomaltase (SI), would lead to serious consequences, such as*major food intolerances. The goal of the proposal is to provide Alectos with quantities of these enzymes for*cross-screening their promising compounds. As these enzymes are large, human proteins, they have to be*produced in eukaryotic cells, to ensure native activity.*The applicant's laboratory is preparing the enzymes in a yeast cell culture system. The funding would allow*production of sufficient quantities of both human intestinal enzymes for cross-screening by the company. If*unwanted activities are seen, the applicant will assist the company in investigating the causes of those activities*and improving the specificity of their compounds.